Regenxbio
RGNX
48 hedge funds and large institutions have $310M invested in Regenxbio in 2015 Q3 according to their latest regulatory filings, with 48 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
54.37% more ownership
Funds ownership: 0% → 54.37% (+54%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$78.5M |
| 2 |
Bain Capital Public Equity Management
Boston,
Massachusetts
|
+$49.4M |
| 3 |
Deerfield Management
New York
|
+$34.1M |
| 4 |
VHCP Management
New York
|
+$27.7M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$25.1M |
Top Sellers
RGNX Hedge Fund Activity: Q3 2015 in Review
48 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q3 2015, worth a combined $310M.
Buyers outnumbered sellers: 48 funds opened new RGNX positions and 0 closed out — a net gain of 48 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $78.5M.
- 48 institutional investors held Regenxbio (RGNX) as of Q3 2015, up from 0 in Q2 2015.
- Funds reported $310M of Regenxbio stock for Q3 2015.
- 48 funds opened new Regenxbio positions in Q3 2015 and 0 closed out, a net change of +48 holders.
- The largest Regenxbio buyer in Q3 2015 was Fidelity Investments, an estimated $78.5M added.
Based on aggregated 13F filings for Q3 2015.